Suvorexant

sleep · nervous · Oral

Suvorexant, a sleep compound. Dual OX1R + OX2R antagonist. Orexin signalling from the hypothalamic lateral nucleus drives wakefulness; blocking… Oral half-life 12 h.

Dual OX1R + OX2R antagonist. Orexin signalling from the hypothalamic lateral nucleus drives wakefulness; blocking it produces hypnosis through a mechanism distinct from GABA potentiation → no GABA-related side effects (no dependence liability as severe as BZs; Schedule IV due to modest abuse potential).

ABSORPTION-RATE PROVENANCE: this value was derived by inverting the one-compartment peak-time relation in 2026-05-26-wave25-ka-from-tmax.ts, whose header claimed every peak time was verbatim from a primary human study. ALL FORTY-FOUR ENTRIES HAVE NOW BEEN CHECKED AND TWENTY-EIGHT FAIL. This one fails because a value appearing nowhere in a verbatim "ranged from 1.5 to 4.0 h", and not its midpoint either. It is DISCLOSED RATHER THAN DELETED: a midpoint of a narrow range is usually inside the true spread, and removing it would fall back on the solver default of 1.0 per hour, which is worse for most of these records.

Pharmacokinetics

• Oral — t½ 12 h · F 82% · ka 1.3 h⁻¹ · Vd 49 L

Sources: PMID:29705869, PMID:20565075